Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation

Brief summary (registry, in English)

The relationship between exercise and atrial fibrillation (AF) seems to follow a J-shaped curve: while moderate activity reduces AF risk, both insufficient and excessive endurance exercise increase susceptibility. In athletes, standard treatments such as antiarrhythmic drugs often provide only partial symptom control and may impair performance through fatigue, chronotropic incompetence and side effects. Pulmonary vein isolation (PVI) may offer a more definitive therapeutic option but carries risks of atrial fibrosis, stiffening, and altered autonomic regulation, which may also influence exercise capacity. The investigators hypothesize that ablation will have a significant impact-either beneficial or detrimental-on the physical performance of athletes with AF. However, existing evidence is limited to small studies with inconsistent findings, underscoring the need for a dedicated study. This prospective, multicentre interventional study will assess the effects of cardiac ablation in 100 endurance athletes with AF. Participants will undergo comprehensive pre- and post-ablation phenotyping, including electrocardiogram (ECG), cardiopulmonary exercise testing (CPET), echocardiography, Holter monitoring, and detailed training data collection (efficiency factor, acute and chronic training load). Clinical follow-up will extend to 12 months post-ablation. The primary endpoint is the change in peak VO₂ (mL/kg/min) measured before ablation and after the procedure. Secondary analyses will explore: * Autonomic adaptations: including changes in maximum heart rate, heart rate recovery, heart rate reserve, and heart rate variability. * Cardiac function: alterations in diastolic and atrial function assessed by echocardiography. * Training and performance: objective measures such as efficiency factor, decoupling, functional threshold power, critical power, and acute and chronic training load. * Technique comparison: differences in outcomes between pulsed field and radiofrequency ablation (e.g. atrial function, troponin release, …). * Sex-specific effects: recognising the underrepresentation of women in sports cardiology research, the investigators will include female athletes according to incidence and evaluate potential differences in treatment response between sexes. * Predictors of AF recurrence in endurance athletes

What you commit to

• Study type: Interventional
• Planned participants: 100
• From 1 Mar 2026 to the primary completion date, 31 Dec 2030
• 5 sites in 2 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.